Elizabeth Mily

CEO

---

Elizabeth A. Mily is a 30+ year healthcare and financial industry veteran, serving most recently as the Executive Vice President, Strategy & Business Development, at Bristol-Myers Squibb. In this role, she oversaw the company strategy and approach to sourcing external innovation, including all business development activities, strategic partnerships, alliance management, mergers and acquisitions, and the company’s broad equity investing portfolio. Elizabeth was appointed to the position in March 2020. Prior to joining Bristol-Myers Squibb, Elizabeth was a senior member of the Global Healthcare Group at Barclays where she led its Lifesciences investment banking business, including coverage of the BioPharma, Life Science Tools and Diagnostics sectors. Prior to joining Barclays, Elizabeth served as Senior Vice President, Corporate Strategy and Development at Thermo Fisher Scientific. Before Thermo Fisher, Elizabeth spent 16 years at Goldman, Sachs & Co., where she was a Managing Director and senior coverage officer within the Healthcare Department of the Investment Banking Division. Elizabeth holds a Master of Science in Foreign Service from Georgetown University and a Bachelor of Arts in German Literature and European History from the Ohio State University. She was also a Fulbright scholar to the Universities of Cologne and Hamburg, Germany and a Congress-Bundestag scholar in Bonn prior to University. Elizabeth serves as a director of Solventum Corporation (NYSE: SOLV), including membership on the Audit and Quality, Science & Technology Committees. She is a director of Ampersand Biomedicines, a private Flagship Pioneering portfolio company.